SCHEMBL442545

SCHEMBL442545

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(C)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
MAPT P10636 4/20 0.49
CYP19A1 P11511 4/20 0.48
PPARG P37231 3/20 0.48
OXER1 Q8TDS5 3/20 0.48
RXRA P19793 2/20 0.48
FFAR1 O14842 2/20 0.48
GRIK1 P39086 2/20 0.46
GRIK2 Q13002 2/20 0.46
PTGS1 P23219 4/20 0.46
F7 P08709 3/20 0.46
F3 P13726 3/20 0.46
PPARA Q07869 3/20 0.46
KMT2A Q03164 2/20 0.46
PPARD Q03181 2/20 0.46
ADORA3 P0DMS8 1/20 0.46
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
NR1I2 O75469 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3840057 1.00 ALDH1A1 (0.49) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL30106405 1.00 ALDH1A1 (0.49) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL3840053 1.00 ALDH1A1 (0.49) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL3840056 1.00 ALDH1A1 (0.49) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL3220464 0.94 ALDH1A1 (0.53) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL3220472 0.94 ALDH1A1 (0.53) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL16744146 0.94 GRIK1 (0.50) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL6908844 0.94 GRIK1 (0.50) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL10688481 0.94 GRIK1 (0.50) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL18571367 0.94 GRIK1 (0.50) ALDH1A1MAPTCYP19A1PPARGOXER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2010508262-A 2010-03-18 JP claimed
EP-2102139-A2 OMEGA-3 LIPID COMPOUNDS Pronova Biopharma Norge AS (NO) 2009-09-23 EP claimed
WO-2008142482-A2 OMEGA-3 LIPID COMPOUNDS PRONOVA BIOPHARMA NORGE AS (US) 2008-11-27 WO claimed
EP-3383380-B1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2023-01-04 EP disclosed
EP-3383380-B1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2023-01-04 EP disclosed
US-20190284129-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2019-09-19 US disclosed
US-20190284129-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2019-09-19 US disclosed
US-20180346408-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2018-12-06 US disclosed
EP-3383380-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE Biozep AS (NO) 2018-10-10 EP disclosed
WO-2017093732-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2017-06-08 WO disclosed
WO-2017093732-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2017-06-08 WO disclosed
US-8034842-B2 Compounds PRONOVA BIOPHARMA NORGE AS (NO) 2011-10-11 US disclosed
US-8034842-B2 Compounds PRONOVA BIOPHARMA NORGE AS (NO) 2011-10-11 US disclosed
EP-2102139-A2 OMEGA-3 LIPID COMPOUNDS Pronova Biopharma Norge AS (NO) 2009-09-23 EP disclosed
US-7550613-B2 alpha-methoxy docosahexanoic acid ethyl ester, alpha-iodo-docosahexanoic acid ethyl ester; antidiabetic for diabetes type 2, cardiovascular disorders, obesity, amyloidosis, prophylaxis; free of 4,7,10,13,16,19-docosahexanoic acid ( DHA), alpha-methyl DHA, alpha-methyl DHA-methyl ester PRONOVA BIOPHARMA NORGE AS (NO) 2009-06-23 US disclosed
US-7550613-B2 alpha-methoxy docosahexanoic acid ethyl ester, alpha-iodo-docosahexanoic acid ethyl ester; antidiabetic for diabetes type 2, cardiovascular disorders, obesity, amyloidosis, prophylaxis; free of 4,7,10,13,16,19-docosahexanoic acid ( DHA), alpha-methyl DHA, alpha-methyl DHA-methyl ester PRONOVA BIOPHARMA NORGE AS (NO) 2009-06-23 US disclosed
WO-2008142482-A2 OMEGA-3 LIPID COMPOUNDS PRONOVA BIOPHARMA NORGE AS (US) 2008-11-27 WO disclosed
WO-2008053340-A1 A COMBINATION PRODUCT COMPRISING AT LEAST ONE LIPID SUBSTITUTED IN THE ALPHA POSITION AND AT LEAST ONE HYPOGLYCEMIC AGENT PRONOVA BIOPHARMA NORGE AS (NO) 2008-05-08 WO disclosed
US-20070088170-A1 Novel compounds PRONOVA BIOPHARMA NORGE AS (NO) 2007-04-19 US disclosed
US-20070088170-A1 Novel compounds PRONOVA BIOPHARMA NORGE AS (NO) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284129-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE APOB, ALOX12, NR1H2 ALDH1A1 417/4885MAPT 3289/4885CYP19A1 884/4885
US-20070088170-A1 Novel compounds FFAR2, GPR119, ALOX12 ALDH1A1 911/4885MAPT 4633/4885CYP19A1 851/4885
US-20180346408-A1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE NR1H2, NR1H3, APOB ALDH1A1 618/4885MAPT 2545/4885CYP19A1 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.